Roswitha Verwer and Dr. Muskaan Bhan share their journey from preclinical validation through regulatory approval, currently at TRL4, pursuing CE Mark and FDA De Novo. The conversation offers insights into how real-time biomarker data can transform women’s reproductive health while overcoming investor skepticism, taboo, and market barriers when solving decades-old clinical blind spots in women’s health.